secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001213900-24-086275
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports Q3 2024 preliminary sales of $6.0M, up 11% YoY; backlog $7.3M
------------------------------------------------------------------------------

- Q3 2024 total sales $6.0M (+11% YoY); nine-month sales $18.7M (+51% YoY).
- Twelve-month sales $23.8M (+46% YoY); production at 77% of ~$30M annual capacity.
- Backlog of orders $7.3M; reflects strong demand as distributors replenish stocks.
- Plans to submit Re-Tain NADA later this year after contract manufacturer resolves FDA issues.
- Conference call on Nov 14, 2024 at 9:00 AM ET to discuss full Q3 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024086275/0001213900-24-086275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024086275/ea0217094-8k_immu.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-086275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer